The District Hospital Santarém to Adopt Biolog Transfusion Solution to Improve Red Blood Cells Traceability
The District Hospital of Santarém, a well-recognized healthcare center located in the central region of Portugal, has chosen Biolog Transfusion Solution to optimize its blood components’ management between its healthcare services and blood transfusion department. In operation since November 2020, this solution provides real-time traceability to red blood cells, from reception to release for transfusion.
Based on RFID, Biolog Transfusion Solution connects healthcare professionals to essential product information. By offering real-time precise physical location for each blood product unit, this cutting-edge technology helps to better drive inventory management and enhance patients’ blood product reservations. Besides, this traceability allows unused red blood cell bags to be more reliably returned to the Blood Bank for potential new patient assignation before the expiration date. Combining the technology with 24/7 accurate digital information contributes to better utilization of available products and in reducing wastage, a key requirement when we know that about 5% of these vital resources can be unavailable for medical usage1.
“The implementation of the Biolog Transfusion Solution proved to be a good tool to improve the traceability of the transfusion process and, consequently, the quality of the service provided by the blood transfusion department. By tracking red blood bags, it’s possible to obtain information on all procedures performed with them, from reception at the department to transfusion at the inpatient service”, said Dra Rute Ribeiro, technical coordinator and responsible for quality of Santarém District Hospital Blood Bank.
“We have worked alongside the District Hospital of Santarém to define the right tools for facing their challenges, and we are pleased to see that Biolog Transfusion Solution meets their needs. At biolog-id we are committed to developing state of the art solutions to ensure the availability and the quality of blood products which will ultimately serve patients”, declares Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id.
“The real time capacity to locate blood components, as well as monitoring transfusion processes is the main achievement made possible by using RFID technology. That is really a forwarding security step!”, explains Dr. João Moura, Director of Santarém District Hospital Blood Bank.
By combining software, equipment, and tags, the modular end-to-end Biolog Transfusion Solution offers traceability of blood components products at every stage of the process. Biolog-id’s flexible approach allows customization of the solution to meet any infrastructure constraints, from blood centers, blood banks, and hospitals.
About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds.
Company URL: www.biolog-id.com
About District Hospital of Santarém:
The District Hospital of Santarém (HDS) is a Corporate Public Entity located in the city of Santarém in the central region of Portugal, in full operation since 1985. The Hospital is part of the Portuguese National Health Service (SNS).
The Hospital was projected in the late 70's with more than 500 beds and the objective of offering a new health infrastructure for the city. The Hospital is equipped with all the main medical and surgical specialties, serving a population of approximately 200,000 inhabitants. It has now a total of 419 beds, where more than 6,000 blood transfusions are delivered each year.
Website URL: https://www.hds.min-saude.pt/
About Xerys Gestion:
Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies. As such, Xerys Gestion supports companies in industries undergoing major transformation to address economic, environmental and societal challenges that have great ambitions for their growth and international expansion. In its market, Xerys Gestion stands out as much for its modus operandi and the strategic and operational support it provides to portfolio companies, as for the range of à la carte investment opportunities offered to investors and the firm’s close relations with them, or its sector-based approach. Lastly, Xerys Gestion has considerable sector expertise, bolstered by a strategic committee made up of recognized specialists and experts in key sectors. Xerys Gestion manages 200 million euros in assets, with a portfolio of nine companies.
For more information visit www.xerys.com or find us on LinkedIn @Xerys.
1 Source: World Health Organization
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005415/en/
Contact information
Contact: Astrid Billard, astrid.billard@biolog-id.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Opens Global Call for Submissions for 2027 Cycle26.1.2026 17:25:00 EET | Press release
The Zayed Sustainability Prize, an affiliate of Erth Zayed Philanthropies and the UAE’s pioneering global award for sustainability and humanitarian innovation, has opened submissions for its 2027 cycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126912976/en/ Winners of the 2026 Zayed Sustainability Prize (Photo: AETOSWire) The Prize carries forward the vision and legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, by supporting those advancing a more inclusive and sustainable world. Now in its 18th year and with a total of US $7.2 million in funds, the Prize invites small and medium enterprises, nonprofit organisations, and high schools to submit innovative solutions across six categories: Health, Food, Energy, Water, Climate Action, and Global High Schools. Commenting on the launch of the 2027 submissions cycle, H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and
2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 16:00:00 EET | Press release
The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication, and 185 nominations for the field of Life Sciences.
Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 15:31:00 EET | Press release
With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 15:00:00 EET | Press release
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Phase II clinical trial in patients with non-infectious anterior uveitis (NIAU). Anterior uveitis is an inflammation of the inner eye including the iris and ciliary body, that typically causes a red, painful, light‑sensitive eye and can lead to vision loss if not treated promptly. NIAU represents 67-90% of uveitis cases in the developed world.1 To treat uveitis a drug must reach the uveal tract inside the eye. Current treatment choices are limited to corticosteroid eye drops and, if insuffic
Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 15:00:00 EET | Press release
Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise environments that demand both performance and trust. “Lucend’s Transparent AI platform analyzes billions of data points daily and provides prescriptive recommendations that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom